Allarity Therapeutics, Inc.: Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Igle ...
manilatimes3h
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program ...
Ottumwa Courier3h
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib ...
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officerto lead the Company’s clinical development programsEli Lilly and Celgene veteran Jose ...
The American Journal of Managed Care20h
Isatuximab Approval Highlights Role of Anti-CD38 Antibody in Myeloma Care
On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients ...